3 Humongous Health-Care Stocks This Weekhttp://www.fool.com/investing/general/2012/11/09/3-humongous-health-care-stocks-this-week-4.aspx Keith Speights
November 9, 2012
With the market experiencing huge losses this week, you might think that it could be difficult to find health-care stocks to include in a list of humongous performers. It's true that there were many biotech stocks dropping by double-digit percentages. However, the week also brought forth several big gainers. Let's take a look at our humongous health-care stocks of the week.
A rare winner
Morquio A is very rare, affecting 1,000 to 1,500 patients in the U.S. and no more than 3,000 patients worldwide. Patients with Morquio A syndrome have skeletal dysplasia and joint abnormalities that make walking quite difficult. The late-stage study found that patients who took a weekly regimen of GALNS significantly improved how far they could walk over a six-minute period.
BioMarin plans to file for regulatory approval to market the drug in the first quarter of 2013. The company's chances for gaining approval look good in light of the phase 3 results.
It's fair to say that expectations have been quite low lately for Intermune. Analysts expected the company to lose $0.84 per share in the quarter. However, Intermune surprised everyone with a loss of only $0.70 per share. The company also reported revenue of $7.5 million, beating analyst estimates of $6.2 million.
Shareholders hope the improved results mean that Intermune will ultimately be successful with Esbriet, a drug